Showing results (1811-1820 of 3,575) with videos related to
Sort By:
Pageof 358
Recenti Progressi in Medicina|June 16, 2026
From Asimov's laws to Kasparov's laws: artificial intelligence, clinical work, and the design of hybrid intelligenceFederico CabitzaRecenti Progressi in Medicina|August 8, 2022
[Artificial intelligence and dermatology.]Giampaolo CollecchiaRecenti Progressi in Medicina|July 16, 2026
[A season of healthcare reforms?]Marco Geddes da FilicaiaRecenti Progressi in Medicina|October 26, 2012
[Role of imaging techniques in the evaluation of chyluria]Artor Niccoli Asabella, Maria Antonia Renna, Antonio Amato Stabile Ianora, et al.Recenti Progressi in Medicina|July 16, 2026
[Sustained clinical benefit with sacituzumab govitecan in metastatic triple-negative breast cancer with extensive cutaneous involvement.]Giacomo Barchiesi, Costanza De Rossi, Elisa Genovesi, et al.Recenti Progressi in Medicina|August 12, 2004
[Diagnosis of the antiphospholipid antibody syndrome in clinical practice]Lorenza Ferrari, Giorgio SavazziRecenti Progressi in Medicina|May 1, 1991
Hyperkalaemia during infusion of hyperosmolar amino acid solutions enriched with branched chain amino acids. Report of two casesS Sartori, I Nielsen, G Pennacchio, et al.Recenti Progressi in Medicina|September 2, 2026
[Aspettative dei pazienti nei confronti di un sistema informatizzato di supporto decisionale clinico basato sull'intelligenza artificiale per migliorare la continuità delle cure dopo il ricovero ospedaliero: uno studio trasversale sulla riabilitazione dopo la protesi totale dell'anca o del ginocchio per l'osteoartrite, con questionario pilota.]Federico Pennestrì, Catia Pelosi, Annalisa Orenti, et al.Recenti Progressi in Medicina|October 5, 2026
[Systemic therapy for advanced triple-negative breast cancer in older women: strategy optimization and effectiveness of sacituzumab govitecan.]Loretta D'OnofrioRecenti Progressi in Medicina|October 5, 2026
[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]Caterina BattagliaPageof 358